Asklepios BioPharmaceutical (AskBio) subsidiary BrainVectis has obtained clearance from the French National Agency for Safety of Medicines and Health Products (ANSM) to carry out the Phase I/II clinical trial of its new gene therapy, BV-101, for treating Huntington’s disease (HD).
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, has received clearance to conduct a...